Analyst Price Targets — HIMS
Latest News for HIMS
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced its Chief Accounting Officer, Irene Becklund will depart the company after more than seven years, effective October 9, 2026. Becklund will then serve as an advisor to the company for several months to assist with the transition. The company will conduct a search for her permanent…
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.15, moving +2.24% from the previous trading session.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for…
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
FDA staff challenged seven compounded peptides, but Hims & Hers continues expanding internationally and strengthening its core healthcare platform beyond longevity therapies. The $400 million JPMorgan receivables facility improves financial flexibility, supporting GLP-1 expansion without relying on dilutive equity financing. The $1.15 billion Eucalyptus acquisition adds 850,000 customers and approximately $450…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HIMS.
U.S. House Trading
No House trades found for HIMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.